Literature DB >> 7922710

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.

Y Pommier1, F Leteurtre, M R Fesen, A Fujimori, R Bertrand, E Solary, G Kohlhagen, K W Kohn.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7922710     DOI： 10.3109/07357909409021413

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  35 in total

1.  Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors:  J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

2.  In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.

Authors:  C Pondarré; D Strumberg; A Fujimori; R Torres-León; Y Pommier
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

3.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.

Authors:  S W Yang; A B Burgin; B N Huizenga; C A Robertson; K C Yao; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.

Authors:  C C Lee; T S Huang
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

5.  Nitric oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective.

Authors:  Birandra K Sinha
Journal:  J Cancer Sci Ther       Date:  2016-10-28

6.  Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.

Authors:  Jean-François Marquis; Isabelle Hardy; Martin Olivier
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways.

Authors:  L Dubrez; I Savoy; A Hamman; E Solary
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

Review 8.  Topoisomerase I interactive drugs in children with cancer.

Authors:  C F Stewart; W C Zamboni; W R Crom; A Gajjar; R L Heideman; W L Furman; W H Meyer; P J Houghton; C B Pratt
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

9.  Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro.

Authors:  E C Sha; M C Sha; S H Kaufmann
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 10.  First-line treatment strategies to improve survival in patients with advanced colorectal cancer.

Authors:  Sharlene Gill; Richard M Goldberg
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.